At the inquiry
Qualified leads
Claimants screened against your firm’s Depo-Provera criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsClaims allege that long-term use of the Depo-Provera contraceptive injection increased the risk of intracranial meningioma, a brain tumor, without adequate warning. We screen claimants against your firm’s criteria.
Discuss a campaignSummary of public information for law firms. Not legal advice.
Delivery models
The right model depends on your intake capacity and acquisition economics.
At the inquiry
Claimants screened against your firm’s Depo-Provera criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsAt the conversation
Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.
For teams ready to take a live call.
How live transfers workAt the retainer
For select programs, acquisition structured around qualified, completed e-signed retainers.
For firms seeking a retained-client model.
About retainer programsThe litigation · October 2026
Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.
SourcesFederal Depo-Provera cases were centralized as MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers.
The FDA approved a label change for Depo-Provera that adds a warning about meningioma.
Judge Rodgers entered an order confirming that plaintiffs’ leadership and Pfizer reached a global settlement in principle. Terms had not been made public at our October 2026 review.
Screening
These are the areas Depo-Provera screening typically covers. The exact questions and thresholds come from your firm.
Talk through your criteriaWhen injections began and how long, or how many, Depo-Provera injections were received.
A meningioma diagnosis, its date and how it was identified.
Surgery, radiation or ongoing monitoring, and the records available.
Whether the claimant already has an attorney for the claim.
Questions
Answers specific to your program are part of the first conversation.
As of our October 2026 review, the June 2026 agreement was in principle and its terms had not been made public. Whether new claims fit your docket is your firm’s decision; we confirm program availability before launch.
Intracranial meningioma, a typically non-cancerous brain tumor, alleged to be linked to long-term use of the injection.
Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.
Sources
Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.
Other torts
Start a conversation
Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.
Book a 30-minute intro call